KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Acquisitions & Divestments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Change in Acquisitions & Divestments data on record, last reported at $2.6 billion in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 1.05% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $11.5 billion, down 23.17%, while the annual FY2025 figure was $11.5 billion, 23.17% down from the prior year.
  • Change in Acquisitions & Divestments reached $2.6 billion in Q4 2025 per REGN's latest filing, down from $3.4 billion in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $4.3 billion in Q3 2024 and bottomed at $416.3 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $2.5 billion, with a median of $2.4 billion recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 140.23% in 2023, then plummeted 46.53% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $416.3 million in 2021, then skyrocketed by 269.3% to $1.5 billion in 2022, then surged by 55.0% to $2.4 billion in 2023, then grew by 8.36% to $2.6 billion in 2024, then dropped by 1.05% to $2.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $2.6 billion in Q4 2025, $3.4 billion in Q3 2025, and $2.2 billion in Q2 2025.